These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21278560)

  • 1. Phase II trial of pegylated liposomal doxorubicin in combination with gemcitabine in metastatic breast cancer patients.
    Jacquin JP; Chargari C; Thorin J; Mille D; Mélis A; Orfeuvre H; Clavreul G; Chaigneau L; Nourissat A; Dumanoir C; Savary J; Merrouche Y; Magné N
    Am J Clin Oncol; 2012 Feb; 35(1):18-21. PubMed ID: 21278560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
    Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
    Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.
    Rivera E; Valero V; Arun B; Royce M; Adinin R; Hoelzer K; Walters R; Wade JL; Pusztai L; Hortobagyi GN
    J Clin Oncol; 2003 Sep; 21(17):3249-54. PubMed ID: 12947059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience.
    Martin-Romano P; Baraibar I; Espinós J; Legaspi J; López-Picazo JM; Aramendía JM; Fernández OA; Santisteban M
    Breast J; 2018 Jul; 24(4):473-479. PubMed ID: 29286192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in Asian women with metastatic breast cancer.
    Wong ZW; Ang PC; Chowbay B; Wong NS; See HT; Khoo KS
    Breast; 2008 Oct; 17(5):517-22. PubMed ID: 18502128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
    Ardavanis A; Mavroudis D; Kalbakis K; Malamos N; Syrigos K; Vamvakas L; Kotsakis A; Kentepozidis N; Kouroussis C; Agelaki S; Georgoulias V;
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of pegylated liposomal doxorubicin (Caelyx) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer.
    Ulrich-Pur H; Kornek GV; Haider K; Kwasny W; Payrits T; Dworan N; Vormittag L; Depisch D; Lang F; Scheithauer W
    Acta Oncol; 2007; 46(2):208-13. PubMed ID: 17453371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
    Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
    Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study.
    Adamo V; Lorusso V; Rossello R; Adamo B; Ferraro G; Lorusso D; Condemi G; Priolo D; Di Lullo L; Paglia A; Pisconti S; Scambia G; Ferrandina G
    Br J Cancer; 2008 Jun; 98(12):1916-21. PubMed ID: 18493232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients.
    Fabi A; Ferretti G; Papaldo P; Salesi N; Ciccarese M; Lorusso V; Carlini P; Carpino A; Mottolese M; Cianciulli AM; Giannarelli D; Sperduti I; Felici A; Cognetti F
    Cancer Chemother Pharmacol; 2006 May; 57(5):615-23. PubMed ID: 16163541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
    Tas F; Guney N; Derin D; Aydiner A; Topuz E
    Int J Clin Oncol; 2008 Apr; 13(2):156-60. PubMed ID: 18463961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.
    Smorenburg CH; de Groot SM; van Leeuwen-Stok AE; Hamaker ME; Wymenga AN; de Graaf H; de Jongh FE; Braun JJ; Los M; Maartense E; van Tinteren H; Nortier JWR; Seynaeve C
    Ann Oncol; 2014 Mar; 25(3):599-605. PubMed ID: 24504445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.
    Pectasides D; Pectasides E; Papaxoinis G; Psyrri A; Pliarchopoulou K; Koumarianou A; Macheras A; Athanasas G; Xiros N; Economopoulos T
    Gynecol Oncol; 2010 Jul; 118(1):52-7. PubMed ID: 20406710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer.
    Rivera E; Valero V; Syrewicz L; Rahman Z; Esteva FJ; Theriault RL; Rosales MM; Booser D; Murray JL; Bast RC; Hortobagyi GN
    J Clin Oncol; 2001 Mar; 19(6):1716-22. PubMed ID: 11251001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
    Pectasides D; Xiros N; Papaxoinis G; Aravantinos G; Sykiotis C; Pectasides E; Psyrri A; Koumarianou A; Gaglia A; Gouveris P; Economopoulos T
    Gynecol Oncol; 2008 Jan; 108(1):47-52. PubMed ID: 17915300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial.
    Del Barco S; Colomer R; Calvo L; Tusquets I; Adrover E; Sánchez P; Rifà J; De la Haba J; Virizuela JA
    Breast Cancer Res Treat; 2009 Jul; 116(2):351-8. PubMed ID: 18941891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
    Poh SB; Bai LY; Chen PM
    Am J Clin Oncol; 2005 Dec; 28(6):540-6. PubMed ID: 16317261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.
    Mirza MR; Lund B; Lindegaard JC; Keldsen N; Mellemgaard A; Christensen RD; Bertelsen K
    Gynecol Oncol; 2010 Oct; 119(1):26-31. PubMed ID: 20638711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
    Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
    Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
    Maltezos E; Amarantidis K; Trichas M; Vasiliadis M; Toromanidou M; Chatzaki E; Karayiannakis A; Tsaroucha A; Romanidis K; Kakolyris S
    Oncology; 2005; 69(6):463-9. PubMed ID: 16374040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.